ZIM Laboratories schedules 42nd AGM; FY26 PAT falls to ₹58 Mn
ZIM Laboratories Limited has scheduled its 42nd Annual General Meeting for June 29, 2026, via Video Conferencing. The company reported a sharp decline in FY26 profitability with PAT falling to ₹58 Mn from ₹1,216 Mn in FY25, while Total Operating Income marginally decreased to ₹3,744 Mn. The AGM agenda includes the adoption of financial statements, re-appointment of directors, and ratification of auditor remuneration.
*this image is generated using AI for illustrative purposes only.
ZIM Laboratories Limited has scheduled its 42nd Annual General Meeting (AGM) for June 29, 2026, at 11:30 A.M. IST via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The company filed its Annual Report for FY26 on June 5, 2026, with BSE Limited and National Stock Exchange of India Limited pursuant to Regulations 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report details a financial performance characterised by a significant decline in profitability and strategic efforts to restore EU-GMP accreditation.
AGM Details and Key Agenda
The Register of Members and Share Transfer Books of the Company will remain closed from Tuesday, June 23, 2026, to Monday, June 29, 2026 (both days inclusive) for the purpose of the AGM. The remote e-voting period begins on Friday, June 26, 2026, at 9:00 A.M. and ends on Sunday, June 28, 2026, at 5:00 P.M. The cut-off date for determining eligible shareholders for e-voting is June 22, 2026. The deemed venue for the AGM shall be the registered office of the Company at Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square, Nagpur – 440013, Maharashtra.
The key agenda items for the AGM include the following:
| Agenda Item | Type of Resolution |
|---|---|
| Adoption of Audited Standalone and Consolidated Financial Statements for FY26 | Ordinary Resolution |
| Re-appointment of Mr. Zulfiquar Kamal (DIN: 01786763), Whole-Time Director, retiring by rotation | Ordinary Resolution |
| Ratification of remuneration of M/s Dhananjay V. Joshi & Associates, Cost Auditors, for FY 2026-27 at ₹5,50,000 plus taxes | Ordinary Resolution |
| Approval for payment of remuneration to Managing Director and Whole-Time Director in case of absence or inadequacy of profits under Schedule V of the Companies Act, 2013, for three financial years commencing FY 2026-27 | Special Resolution |
Ms. Roshni Jethani, Company Secretary in Practice, has been appointed as the Scrutinizer to scrutinize the remote e-voting and e-voting process on the date of the AGM.
FY26 Financial Performance
The company reported a sharp contraction in profitability for FY26. Total Operating Income stood at ₹3,744 Mn, a marginal decline of 1.2% from ₹3,790 Mn in the previous year. Profit After Tax (PAT) fell significantly to ₹58 Mn from ₹1,216 Mn in FY25, with PAT margins contracting to 1.6% from 3.2%. EBITDA declined by 16.4% year-on-year to ₹414 Mn. The following table summarises the key financial metrics:
| Metric | FY26 | FY25 |
|---|---|---|
| Total Operating Income | ₹3,744 Mn | ₹3,790 Mn |
| EBITDA | ₹414 Mn | ₹495 Mn |
| EBITDA Margin | 11.0% | 13.0% |
| PAT | ₹58 Mn | ₹1,216 Mn |
| PAT Margin | 1.6% | 3.2% |
| Export Revenue | ₹3,150 Mn | ₹3,125 Mn |
| Export Revenue Growth (YoY) | 0.8% | - |
| NIP + OTF Sales Revenue | ₹566 Mn | - |
| R&D Expenditure (% of Total Operating Income) | 8.3% | - |
| Total Borrowings | ₹1,230 Mn | ₹1,122 Mn |
| Net Worth | ₹2,961 Mn | - |
| Finance Costs | ₹132 Mn | ₹114 Mn |
Exports remained the primary revenue driver, contributing 84% of Total Operating Income at ₹3,150 Mn, while domestic revenues accounted for 16%. Finance costs increased from ₹114 Mn to ₹132 Mn in FY26, reflecting an increase in total borrowings from ₹1,122 Mn to ₹1,230 Mn, deployed towards plant and equipment upgrades in support of infrastructure expansion.
Strategic Priorities and Capital Allocation
The company's foremost strategic priority for FY27 is the restoration of EU-GMP accreditation to unlock European market entry. In June 2025, an EU-GMP audit identified deficiencies in manual control and documentation processes, leading to a pause in accreditation. The company submitted CAPA responses encompassing manpower reinforcement, investment in new plant and equipment, and a comprehensive overhaul of systems and processes, which have been formally accepted by the remediation committee and auditors. ZIM completed a preferential issue of 47,64,497 equity shares at an issue price of ₹73.46 per share to Florintree Trinex LLP, raising approximately ₹350 million. These funds are being deployed towards CAPA remediation infrastructure, completing the dedicated NIP suite for EU business, and expanding the Nutraceuticals suite.
Business Segment and Geographic Performance
The Pharmaceuticals division continued to be the primary revenue driver, accounting for 80% of Total Operating Income at ₹2,990 Mn, while the Nutraceuticals division contributed 20% at ₹754 Mn. Geographically, the Americas and MENA were the largest markets at ₹1,298 Mn each, followed by Asia (excluding India) at ₹1,123 Mn and India at ₹594 Mn. The company completed 57 regulatory filings across key geographies, comprising 14 NIP filings, 29 OTF filings, and 14 FF filings.
Director Remuneration and Shareholding
For FY 2025-26, the remuneration paid to executive directors is detailed below:
| Director | Fixed Remuneration (₹) | Total Remuneration (₹) |
|---|---|---|
| Dr. Anwar Daud, Managing Director | 1,54,08,000 | 1,54,08,000 |
| Mr. Zulfiquar Kamal, Director (Finance) | 91,88,000 | 1,01,88,000 |
| Mr. Niraj Dhadiwal, Executive Director | 84,95,000 | 95,81,400 |
| Mr. Prakash Sapkal, Executive Director | 75,25,000 | 85,05,000 |
The proposed remuneration range for the Managing Director is a fixed salary of ₹130.00 Lakhs p.a. to ₹300.00 Lakhs p.a., plus commission on profit up to 2.0% of the net profits of the Company p.a. For the Whole-Time Director (Mr. Zulfiquar Kamal), the proposed fixed pay range is ₹87.50 Lakhs p.a. to ₹250.00 Lakhs p.a., plus commission on profit up to 1.0% of the net profits of the Company p.a. The securities held by the directors as on March 31, 2026, are as follows:
| Name of Director | No. of Equity Shares Held | % of Paid-up Share Capital |
|---|---|---|
| Dr. Anwar Siraj Daud | 1,33,36,320 | 24.90% |
| Mr. Zulfiquar Murtaza Kamal | 11,95,260 | 2.23% |
R&D and Innovation
Research and Development expenditure for FY26 was ₹311 Mn, representing 8.3% of Total Operating Income. The company has invested a total of ₹1,503 Mn in R&D over the last five years on Opex, Facility, and BE studies. Development of all 12 NIP products is complete, and the company is in advanced Bio-Equivalence studies for select products. The focus remains on advancing patient-centric drug delivery solutions and strengthening its presence in Developed and Pharmerging markets.
Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE518E01015/208b8668c4804404.pdf
Historical Stock Returns for Zim Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.79% | +6.63% | +22.61% | +70.13% | +13.33% | +6.51% |
What is the expected timeline for the restoration of EU-GMP accreditation, and when can revenue contributions from the European market realistically begin?
How will the company manage the increased finance costs and total borrowings if profitability does not recover in FY27?
What specific revenue growth targets has management set for the new NIP and Nutraceutical suites once the EU-GMP compliance issues are resolved?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
